Cat. No. 1467
Alternative Name: Daunomycin
Chemical Name: (8S,10S)-8-Acetyl-10-[(3-amino-2,3,
Biological ActivityAnticancer agent that is clinically used to treat nonlymphocytic leukemia. Inhibits RNA and DNA synthesis and causes DNA fragmentation in vivo. Reduces tau mRNA levels in vitro.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Dickey et al (2006) Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol.Neurodegen. 1 6. PMID: 16930453.
Laurent and Jaffrezou (2001) Signaling pathways activated by daunorubicin. Blood 98 913. PMID: 11493433.
Gewirtz (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem.Pharmacol. 57 727. PMID: 10075079.
Aubel-Sadron and Londos-Gagliardi (1984) Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 66 333. PMID: 6380596.
If you know of a relevant reference for Daunorubicin hydrochloride please let us know.
Citations are publications that use Tocris products. Selected citations for Daunorubicin hydrochloride include:
Jones et al (2013) An alternative direct compound dispensing method using the HP D300 digital dispenser. PLoS One 18 367. PMID: 23708834.
Do you know of a great paper that uses Daunorubicin hydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Daunorubicin hydrochloride, supplier, RNA, synthesis, inhibitors, inhibits, antibiotics, chemotherapeutics, Tocris Bioscience, DNA, RNA and Protein Synthesis Inhibitor products
Find multiple products by catalog number
New Products in this Area
RAD51 recombinase inhibitorPCNA I1
PCNA inhibitorPladienolide B
mRNA splicing inhibitor; antitumorLin28 1632
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor
June 14 - 17, 2017
Boston, MA, USA